+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID07417189

Phase III Study of Oral ABSK141 to Evaluate Safety and Effectiveness in Adults With Advanced Solid Tumors Having KRAS G12D Mutation

Led by Abbisko Therapeutics Co, Ltd · Updated on 2026-03-11

401

Participants Needed

1

Research Sites

30 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating an investigational drug called ABSK141 in adults with advanced solid tumors that have a specific KRAS G12D mutation. This early phase III study aims to assess the safety, tolerability, pharmacokinetics how the drug moves through the body, and to find the best dose for further testing. The study focuses on patients whose cancers have progressed after standard treatments or who have no current standard treatment options. The study starts with a dose escalation phase where patients receive oral ABSK141 tablets at different doses 400 mg, 800 mg, 1200 mg, or a recommended dose for expansion once daily. This phase includes a single-dose run-in to assess pharmacokinetics followed by continuous daily dosing until disease progression. Following this, an expansion phase will investigate the recommended doses to further evaluate safety and efficacy in selected tumor types. The phase II portion will continue to study ABSK141 at the recommended phase 2 dose administered daily until disease progression. Participants will undergo regular monitoring for dose-limiting toxicities and adverse events from consent through 30 days after the last dose. Researchers will assess drug levels within 72 hours after dosing and evaluate tumor response using standard imaging criteria over up to 24 months. Additional outcomes include progression-free survival, overall survival, and duration of response. The study involves frequent safety and efficacy assessments to understand how ABSK141 affects patients with KRAS G12D mutant advanced solid tumors.

CONDITIONS

Brief Title

A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 )

Research Team

Y

Yu Zhang, Bachelor

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here